C2N Diagnostics

Dana and his family noticed he was having trouble with his memory. His health care professional turned to the Precivity™ blood tests for answers.

The Precivity tests are innovative new blood tests intended for use in patients 50 and older with signs or symptoms of mild cognitive impairment or dementia.

These tests aid health care professionals in the detection of amyloid plaques in the brain, a pathological hallmark of Alzheimer's disease, and inform medical management and treatment decisions.

Watch Dana’s story at
https://youtu.be/32opzOWnyJI

Learn more at www.preciviyAD.com

www.preciviyad.com

C2N is honored that the Human Proteome Organization (HUPO), the nonprofit international scientific organization that represents and promotes proteomics on a global stage, has named members of the scientific teams at C2N Diagnostics and the Bateman Lab and the Holtzman Lab at Washington University School of Medicine as recipients of the HUPO 2025 Scientific and Technology Award. Dr. Joel Braunstein accepted the award on behalf of C2N and Washington University.

HUPO says it selected the C2N and WashU Medicine teams because their “exceptional achievements have significantly advanced the field of proteomics. Each award recognizes excellence, innovation, and impactful contributions to the global scientific community.”

Congratulations to all the scientists recognized for this award in excellence!

C2N Diagnostics is proud to participate in the Gerontological Society of America (GSA) 2025 Annual Scientific Meeting in Boston, MA, November 12 - 15. C2N will be sharing The Effect of Patient Age, S*x, Race, and Ethnicity on Decision-Making Around An Alzheimer's Disease Blood Test: QUIP II Study Results at Poster Session (7010) Alzheimer’s Disease and Related Dementias on Wednesday, November 12 from 6:00 - 7:15 PM in the Hynes Convention Center Room - Exhibit Hall C - Poster Board 53.

Please visit our C2N exhibit booth to talk with our team.